SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-330158"
 

Sökning: id:"swepub:oai:DiVA.org:uu-330158" > Shaping the Tumor S...

Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.

Svensson, Emma (författare)
Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab
Milenova, Ioanna (författare)
Uppsala universitet,Institutionen för immunologi, genetik och patologi,Science for Life Laboratory, SciLifeLab,Vrije Univ, Netherlands
Wenthe, Jessica (författare)
Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab
visa fler...
Ståhle, Magnus (författare)
Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab
Leja-Jarblad, Justyna, 1982- (författare)
Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab,Immuneed AB, Uppsala, Sweden
Ullenhag, Gustav (författare)
Uppsala universitet,Experimentell och klinisk onkologi,Science for Life Laboratory, SciLifeLab
Dimberg, Anna (författare)
Uppsala universitet,Vaskulärbiologi,Science for Life Laboratory, SciLifeLab
Moreno, Raphael (författare)
IDIBELL-Institute Catalá d'Oncologia, Barcelona, Spain
Alemany, Ramon (författare)
IDIBELL-Institute Catalá d'Oncologia, Barcelona, Spain
Loskog, Angelica S., 1973- (författare)
Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab,Lokon Pharma AB, Uppsala, Sweden
visa färre...
 (creator_code:org_t)
2017
2017
Engelska.
Ingår i: Clinical Cancer Research. - 1078-0432 .- 1557-3265. ; 23:19, s. 5846-5857
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Purpose: Pancreatic cancer is a severe indication with short expected survival despite surgery and/or combination chemotherapeutics. Checkpoint blockade antibodies are approved for several cancer indications, but pancreatic cancer has remained refractory. However, there are clinical data suggesting that stimulation of the CD40 pathway may be of interest for these patients. Oncolytic viruses armed with immunostimulatory genes represent an interesting approach. Herein, we present LOAd703, a designed adenovirus armed with trimerized CD40L and 4-1BBL that activates the CD40 and 4-1BB pathways, respectively. As many cells in the tumor stroma, including stellate cells and the infiltrating immune cells, express CD40 and some 4-1BB, we hypothesize that LOAd703 activates immunity and simultaneously modulates the biology of the tumor stroma.Experimental Design: Tumor, stellate, endothelial, and immune cells were infected by LOAd703 and investigated by flow cytometry, proteomics, and functional analyses.Results: LOAd703-infected pancreatic cell lines were killed by oncolysis, and the virus was more effective than standard-of-care gemcitabine. In in vivo xenograft models, LOAd703 efficiently reduced established tumors and could be combined with gemcitabine for additional effect. Infected stellate and tumor cells reduced factors that promote tumor growth (Spp-1, Gal-3, HGF, TGFβ and collagen type I), while chemokines were increased. Molecules involved in lymphocyte migration were upregulated on infected endothelial cells. Dendritic cells were robustly stimulated by LOAd703 to produce costimulators, cytokines and chemokines, and such DCs potently expanded both antigen-specific T cells and NK cells.Conclusions: LOAd703 is a potent immune activator that modulates the stroma to support antitumor responses. Clin Cancer Res; 1-12. ©2017 AACR.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinsk bioteknologi -- Medicinsk bioteknologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Medical Biotechnology -- Medical Biotechnology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy